|
1
|
Cooper C, Campion G and Melton LJ III: Hip
fractures in the elderly: A world-wide projection. Osteoporos Int.
2:285–289. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Melton LJ III, Chrischilles EA, Cooper C,
Lane AW and Riggs BL: Perspective. How many women have
osteoporosis? J Bone Miner Res. 7:1005–1010. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holroyd C, Cooper C and Dennison E:
Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab.
22:671–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zallone A: Direct and indirect estrogen
actions on osteoblasts and osteoclasts. Ann N Y Acad Sci.
1068:173–179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nelson HD, Humphrey LL, Nygren P, Teutsch
SM and Allan JD: Postmenopausal hormone replacement therapy:
Scientific review. JAMA. 288:872–881. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ishida Y and Kawai S: Comparative efficacy
of hormone replacement therapy, etidronate, calcitonin,
alfacalcidol, and vitamin K in postmenopausal women with
osteoporosis: The Yamaguchi osteoporosis prevention study. Am J
Med. 117:549–555. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ross RK, Paganini-Hill A, Wan PC and Pike
MC: Effect of hormone replacement therapy on breast cancer risk:
Estrogen versus estrogen plus progestin. J Natl Cancer Inst.
92:328–332. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grady D, Gebretsadik T, Kerlikowske K,
Ernster V and Petitti D: Hormone replacement therapy and
endometrial cancer risk: A meta-analysis. Obstet Gynecol.
85:304–313. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McClung M, Harris ST, Miller PD, Bauer DC,
Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK and Lewiecki EM:
Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug
holiday. Am J Med. 126:13–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Russell RG and Rogers MJ: Bisphosphonates:
From the laboratory to the clinic and back again. Bone. 25:97–106.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Udell JA, Fischer MA, Brookhart MA,
Solomon DH and Choudhry NK: Effect of the women's health initiative
on osteoporosis therapy and expenditure in Medicaid. J Bone Miner
Res. 21:765–771. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Banu J, Varela E and Fernandes G:
Alternative therapies for the prevention and treatment of
osteoporosis. Nutr Rev. 70:22–40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee BJ and Lee K: Discrimination and
proper use of polygoni multiflori radix, cynanchi wilfordii radix,
and cynanchi auriculati radix in Korea: A descriptive review. Evid
Based Complement Alternat Med. 2015:8273802015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choi DH, Lee YJ, Kim JS, Kang DG and Lee
HS: Cynanchum wilfordii ameliorates hypertension and endothelial
dysfunction in rats fed with high fat/cholesterol diets.
Immunopharmacol Immunotoxicol. 34:4–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee HS, Choi JH, Kim YE, Kim IH, Kim BM
and Lee CH: Effects of the cynanchum wilfordii ethanol extract on
the serum lipid profile in hypercholesterolemic rats. Prev Nutr
Food Sci. 18:157–162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shan L, Liu RH, Shen YH, Zhang WD, Zhang
C, Wu DZ, Min L, Su J and Xu XK: Gastroprotective effect of a
traditional Chinese herbal drug ‘Baishouwu’ on experimental gastric
lesions in rats. J Ethnopharmacol. 107:389–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim MS, Baek JH, Park JA, Hwang BY, Kim
SE, Lee JJ and Kim KW: Wilfoside K1N isolated from Cynanchum
wilfordii inhibits angiogenesis and tumor cell invasion. Int J
Oncol. 26:1533–1539. 2005.PubMed/NCBI
|
|
18
|
Chang A, Kwak BY, Yi K and Kim JS: The
effect of herbal extract (EstroG-100) on pre-, peri-and
post-menopausal women: A randomized double-blind,
placebo-controlled study. Phytother Res. 26:510–516. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Compston J: Clinical and therapeutic
aspects of osteoporosis. Eur J Radiol. 71:388–391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hui SL, Slemenda CW and Johnston CC Jr:
Age and bone mass as predictors of fracture in a prospective study.
J Clin Invest. 81:1804–1809. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cummings SR, Black DM, Nevitt MC, Browner
W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J and Vogt TM:
Bone density at various sites for prediction of hip fractures. The
Study of Osteoporotic Fractures Research Group. Lancet. 341:72–75.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Melton LJ III, Atkinson EJ, O'Fallon WM,
Wahner HW and Riggs BL: Long-term fracture prediction by bone
mineral assessed at different skeletal sites. J Bone Miner Res.
8:1227–1233. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teitelbaum SL: Bone resorption by
osteoclasts. Science. 289:1504–1508. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suda T, Nakamura I, Jimi E and Takahashi
N: Regulation of osteoclast function. J Bone Miner Res. 12:869–879.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harada S and Rodan GA: Control of
osteoblast function and regulation of bone mass. Nature.
423:349–355. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kirstein B, Chambers TJ and Fuller K:
Secretion of tartrate-resistant acid phosphatase by osteoclasts
correlates with resorptive behavior. J Cell Biochem. 98:1085–1094.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Minkin C: Bone acid phosphatase:
Tartrate-resistant acid phosphatase as a marker of osteoclast
function. Calcif Tissue Int. 34:285–290. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Simonet WS, Lacey DL, Dunstan CR, Kelley
M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et
al: Osteoprotegerin: A novel secreted protein involved in the
regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hauschka PV, Lian JB, Cole DE and Gundberg
CM: Osteocalcin and matrix Gla protein: Vitamin K-dependent
proteins in bone. Physiol Rev. 69:990–1047. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brown JP, Delmas PD, Malaval L, Edouard C,
Chapuy MC and Meunier PJ: Serum bone Gla-protein: A specific marker
for bone formation in postmenopausal osteoporosis. Lancet.
1:1091–1093. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stein GS, Lian JB, Van Wijnen AJ, Stein
JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY and Pockwinse
SM: Runx2 control of organization, assembly and activity of the
regulatory machinery for skeletal gene expression. Oncogene.
23:4315–4329. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakashima K, Zhou X, Kunkel G, Zhang Z,
Deng JM, Behringer RR and de Crombrugghe B: The novel zinc
finger-containing transcription factor osterix is required for
osteoblast differentiation and bone formation. Cell. 108:17–29.
2002. View Article : Google Scholar : PubMed/NCBI
|
